The International Space Station (ISS) U.S. National Laboratory is managing 13 separate payloads launching to the orbiting laboratory to advance basic and applied research in several disciplines
Evotec SE and Indivumed GmbH announced recently that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer (“CRC”)
HitGen Inc. announced recently that HitGen Inc. and Kaken Pharmaceutical Co., Ltd. have entered into a license agreement to develop a novel class of drugs
In one of the largest studies of its kind, researchers used CRISPR technology to disrupt every gene in over 300 cancer models from 30 cancer types and discover thousands of key genes essential for cancer’s survival
A half dozen University of Connecticut (UConn) researchers are now working to identify potential new drugs to treat a wide range of diseases and conditions through a unique partnership that offers access to cutting-edge artificial intelligence (AI) technology and screening compounds at no cost
SomaLogic, Inc. announced today that it has entered into a collaborative agreement with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the agreement terms, SomaLogic will analyze ~5000 proteins in each of at least 15,000 clinical samples from Janssen to identify and validate protein biomarkers for use by Janssen and SomaLogic in predicting, diagnosing, monitoring, and treating disease
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has successfully expanded the clinical supply of Annamycin for its on-going clinical trials via BSP Pharmaceuticals S.p.A. (www.bsppharmaceuticals.com) in Latina, Italy
Universal access to medicine could come via open source drug discovery, argues lecturer Dr Alice Motion. She works to make drug discovery less secretive, so that more people can help find the pharmaceuticals the world needs
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Therapy designation for PB2452, a novel reversal agent for the antiplatelet drug ticagrelor
The U.S. Food and Drug Administration today approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato
|
|
|
|
|
|
|
|
|